The effect of PEG in the treatment of hepatic encephalopathy

PEG-Lactulose versus lactulose in the treatment of hepatic encephalopathy in cirrhotic patients in Shariati hospital.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015083117719N2

Enrollment

Registered

2015-10-02

Start date

2015-09-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis. Other and unspecified cirrhosis of liver

Interventions

Intervention 1: Lactulose group (control group) will receive either 20 to 30 grams of lactulose (at least 3 doses in 24 hours) orally or by a nasogastric tube, or 200 grams of lactulose enema by a rec

Treatment - Drugs

Lactulose group (control group) will receive either 20 to 30 grams of lactulose (at least 3 doses in 24 hours) orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube for 24

Polyethylene Glycol (PEG) – lactulose group (intervention group), will receive a single dose of 4 liters of PEG solution contain PEG in an amount of 280 grams additional to standard treatment that lac

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age 18 to 80 years old; Documented cirrhosis with any underlying etiology; Any grade of hepatic encephalopathy; Signed informed consent by patient or his/her LARs (if there is an imperfect level of consciousness) Exclusion criteria: Acute liver failure that was defined as the onset of severe acute liver injury with encephalopathy and international normalized ratio (INR) of =1.5 in a patient without cirrhosis or preexisting liver disease; Altered mental status due to a diagnosis other than hepatic encephalopathy; Patient's or his/her LAR unwillingness to this trial; Hemodynamic instability which needs vasopressors for resuscitation; Pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of hepatic encephalopathy. Timepoint: At presentation and 24 h later. Method of measurement: HESA (Hepatic Encephalopathy Scoring Algorithm).	—

Secondary

Measure	Time frame
Blood level of ammonia. Timepoint: At presentation and 24 h later. Method of measurement: Blood sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadreza Naderian

Tehran University of Medical Sciences

naderian.mr@gmail.com+98 912 245 4909

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026